License agreement with Teva

Sinclair IS Pharma plc

License agreement with Teva for episil®

LONDON, UK, 31 August 2011- Sinclair IS Pharma plc (AIM:SPH.L) ("Sinclair IS"), the international specialty pharma company, announces that it has signed a license agreement with Teva Pharmaceutical Industries Ltd ("Teva") for Sinclair IS's oncology supportive care product, episil®. Under the terms of the agreement, Teva will have the exclusive commercialisation rights for episil® in Germany, Spain, Poland, Switzerland and the Czech Republic. Sinclair IS retains an option to co-promote episil® in Germany and Spain where it has its own direct sales force. Financial details of the license deal have not been disclosed.

episil® is a patented oral spray indicated for local treatment of pain associated with oral mucositis, a serious side effect of chemotherapy and radiotherapy during cancer treatment.

episil® creates a strong bioadhesive FluidCrystal® film that protects sensitive and sore areas of the mouth providing prolonged pain reduction of at least eight hours(1) Following the merger with IS Pharma plc, Sinclair IS owns the licensing and distribution rights to episil® across Europe (excluding the Nordic countries).

Teva expects to launch episil® in the final quarter of 2011.

 Chris Spooner, CEO of Sinclair IS said:

"A key part of the rationale behind the merger with IS Pharma was to broaden the sales reach of the IS portfolio through Sinclair's direct country and regional operations. This is the first in what we expect to be a number of marketing and co-marketing partnerships. episil® is a cornerstone of our supportive oncology portfolio and we look forward to working with Teva as we drive sales of this product."

- ENDS -

(1) Tiberg F, Cavallin-Stahl E, et al. Support Cancer Care 2009

For further information please contact:

About Oral Mucositis

Oral mucositis is a severe side-effect of cancer chemotherapy or radiotherapy. It is caused by damage to the DNA in the basal epithelial cell lining of the mouth leading to decreased cell proliferation ability which may result in ulceration and opportunistic mouth infections.

Oral mucositis is often a dose-limiting factor in the treatment of cancer. In more severe cases, oral mucositis can be extremely painful, preventing the patient from eating and necessitating hospitalization for re-hydration, opiate pain medication and total parenteral nutrition.

About episil®

episil® represents a new concept for local treatment of pain associated with oral mucositis.

The product is administered as a lipid-based liquid that spreads on the intra-oral mucosal surfaces and transforms to a strongly bioadhesive FluidCrystal film that mechanically protects the sensitized and sore epithelium of the oral cavity. episil® is conveniently administered from a ready to use multi-dose device.

episil® has been demonstrated to give an immediate and significant reduction of pain caused by oral mucositis. This effect was maintained over at least eight hours following administration.

episil® is developed by Camurus AB, a privately owned Swedish life science company. It has been registered as a medical device across Europe and has been granted the CE mark. The product is protected by patent until 2025. Sinclair IS Pharma has distribution rights for the EU territories plus Switzerland with the exception of Sweden, Denmark, Finland, Norway and Iceland where Camurus will commercialize the product directly.

About Teva

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 42,000 people around the world and reached $16.1 billion in net sales in 2010

About Sinclair IS Pharma plc- see www.sinclairispharma.com

Sinclair IS Pharma is an international specialty pharmaceutical company focused on treatments in dermatology, wound care, oncology support and critical care through advanced surface technology and innovative delivery systems. The Company has a growing sales and marketing operation with a direct sales presence in the top five European markets and an extensive marketing partner network across selected developed & emerging markets.